# US 5,326,559 A · Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,326,559 A - Document ID: US5326559A - Status: Granted - Kind: A - Application number: 07/701,219 - Filed: 1991-05-16 - Granted: 1994-07-05 - Earliest claimed: 1991-05-16 - Inventors: D. Douglas Miller - Web page: https://patentgrep.com/patent/US5326559A ## CPC - C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} - A61K 47/62: the modifying agent being a protein, peptide or polyamino acid - C07K 14/5406: {IL-4} - C07K 14/5412: {IL-6} - C07K 14/55: IL-2 - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2319/00: Fusion polypeptide - C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin - C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention features a method for treating a patient suffering from accelerated atherosclerosis in a patient suffering from vascular damage, e.g., damage caused by percutaneous transluminal coronary angioplasty (PTCA), heart transplantation, or coronary vein graft. The method includes administering to the patient a molecule which is capable of specifically binding to a interleukin receptor expressed on a cell of the patient which contributes to the process of accelerated atherosclerosis. The molecule is capable of decreasing the viability of the cells. ## Claims ### Claim 1 A method for inhibiting accelerated atherosclerosis in a patient suffering from vascular injury, said method comprising administering to said patient a molecule which is capable of specifically binding to an interleukin-2 receptor expressed on a cell of said patient which contributes to the process of accelerated atherosclerosis, said molecule being capable of decreasing the viability of said cell, said molecule being a hybrid molecule comprising a first and a second portion joined together covalently, said first portion comprising a cytotoxin capable of decreasing cell viability and said second portion comprising interleukin-2 or an antibody capable of binding to the interleukin-2 receptor. ### Claim 2 (depends on 1) The method of claim 1 wherein said cell is a lymphocyte. ### Claim 3 (depends on 1) The method of claim 1 wherein said interleukin-2 receptor is a high affinity interleukin-2 receptor. ### Claim 4 (depends on 1) The method of claim 1 wherein said vascular injury is caused by angioplasty. ### Claim 5 (depends on 1) The method of claim 1 wherein said vascular injury is caused by coronary vein graft. ### Claim 6 (depends on 1) The method of claim 1 wherein said vascular injury is caused by cardiac transplant surgery. ### Claim 7 (depends on 1) The method of claim 1 wherein said molecule kills cells bearing said interleukin-2 receptor. ### Claim 8 (depends on 1) The method of claim 1 wherein said cytotoxin is a fragment of a peptide toxin which is enzymatically active but which does not possess generalized eukaryotic receptor binding activity. ### Claim 9 (depends on 8) The method of claim 8 wherein said fragment of a peptide toxin comprises fragment A of diphtheria toxin and enough of fragment B of diphtheria toxin to facilitate translocation into the cytosol. ### Claim 10 (depends on 9) The method of claim 9 wherein said molecule is DAB.sub.389 IL-2. ### Claim 11 (depends on 9) The method of claim 9 wherein said molecule is DAB.sub.486 IL-2.